rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
RANBAXY LABORATORIES LTD. - Ranbaxy Laboratories Ltd reply to clarification sought by the exchange
< Back
11 Dec 2014
The Exchange had sought clarification with respect to the following statement of Ranbaxy Laboratories Ltd on December 8, 2014 :&lt;BR&gt;&lt;BR&gt;&quot;On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy&apos;s April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws.&lt;BR&gt;&lt;BR&gt;Ranbaxy is pleased with this verdict, and is committed to serving patients, prescribers and the US healthcare system.&quot;&lt;BR&gt;&lt;BR&gt;Ranbaxy Laboratories Ltd has vide its emails dated December 8, 2014 and December 11, 2014 respectively clarified that:&lt;BR&gt;&lt;BR&gt;1. &quot;Company had issued a Press Release on April 15, 2008 titled &quot;Ranbaxy and Astrazeneca reach Agreement in Esomeprazole Patent Litigation&quot; and details of the Settlement as agreed at that time were disclosed through this Press Release to Stock Exchanges.&quot;&lt;BR&gt;&lt;BR&gt;2. &quot;Company has not paid any compensation / penalty in the matter.&quot;
View all announcements for RANBAXY LABORATORIES LTD. Source: BSE India